portada

Últimas Noticias en Farma y Tecnología

Recibe diariamente las últimas novedades y cambios en el mundo de la contratación pública, la industria farmacéutica y la tecnología sanitaria.

Suscribirme a la newsletter

noticia
  1. Inicio
  2. Tender Data
  3. Tender Data
  4. Noticias

NOTICIA DE CONTRATACIÓN

Biogen va a lanzar Humira biosimilar en Europa en octubre

Biogen (NASDAQ:BIIB) and development partner Samsung Bioepis announce the resolution of a patent dispute with AbbVie (NYSE:ABBV) over its HUMIRA (adalimumab) biosimilar.

17 Abril 2018 | Fuente original

Compartir
Sin nombre.jpg

Under the terms of the settlement, AbbVie will grant patent licenses for the biosimilar, branded as IMRALDI, in Europe on a country-specific basis. Biogen and Samsung Bioepis will make royalty payments to AbbVie. Specific financial terms are not disclosed.

Biogen expects to launch IMRALDI, its third approved biosimilar, in Europe on October 16. BENEPALI, a biosimilar of Amgen's ENBREL (etanercept), and FLIXABI, a biosimilar of J&J's REMICADE (infliximab) were OK'd there in 2016.

The license period in the U.S. will begin on June 30, 2023.

Separately, Amgen's U.S. entry will happen on January 31, 2023.

Previously: Biogen's Humira biosimilar OK'd in Europe (Aug. 25, 2017)

 

Leer noticia completa

Habla con Nuestros Expertos

Descubre cómo podemos ayudarte a alcanzar tus objetivos
 en el mercado sanitario.

Contacto